Lynlee M Stevey-Rindenow, Marissa Saenz, Vivian La, Craig Franklin, Ari Aycock-Williams, Patrick T Fueger
{"title":"Pharmacokinetics of extended-release buprenorphine in female Yorkshire swine (Sus scrofa domestica).","authors":"Lynlee M Stevey-Rindenow, Marissa Saenz, Vivian La, Craig Franklin, Ari Aycock-Williams, Patrick T Fueger","doi":"10.2460/ajvr.24.10.0313","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine the pharmacokinetics of extended-release buprenorphine (XRB) in adult swine. We hypothesized that after a single SC administration of XRB in swine, buprenorphine plasma concentrations would be at or above the therapeutic threshold of 0.1 ng/mL and would not result in major injection site reactions.</p><p><strong>Methods: </strong>Extended-release buprenorphine was administered once SC to 2 cohorts of adult female Yorkshire swine at low (0.2 mg/kg) and high doses (0.4 mg/kg). Blood was collected from an indwelling jugular catheter prior to and after XRB administration for 13 total time points. Buprenorphine plasma concentrations were analyzed by HPLC-MS, and pharmacokinetics were performed using a noncompartmental analysis.</p><p><strong>Results: </strong>Extended-release buprenorphine was present in plasma at the therapeutic concentration of 0.1 ng/mL or above beginning at 8 hours and maintaining throughout 96 hours for all animals in both cohorts. Average plasma buprenorphine levels for both cohorts reached therapeutic concentrations starting at 1.5 hours and were maintained above therapeutic concentrations throughout 96 hours. The low-dose cohort's (n = 3) average half-life was 212.6 ± 107.1 hours, and the high-dose cohort's (n = 2) was 63.8 and 48.9 hours, respectively. The histology of SC sites revealed mild injection site reactions characterized by granulomatous inflammation with intralesional cholesterol cleft formation.</p><p><strong>Conclusions: </strong>All animals reached and maintained therapeutic buprenorphine plasma concentrations of 0.1 ng/mL by 8 hours and maintained it to the end of the study at 96 hours.</p><p><strong>Clinical relevance: </strong>Extended-release buprenorphine at either dose provides therapeutic levels of plasma buprenorphine, and therefore its use should be further investigated in swine.</p>","PeriodicalId":7754,"journal":{"name":"American journal of veterinary research","volume":" ","pages":"1-9"},"PeriodicalIF":1.3000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of veterinary research","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.2460/ajvr.24.10.0313","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To determine the pharmacokinetics of extended-release buprenorphine (XRB) in adult swine. We hypothesized that after a single SC administration of XRB in swine, buprenorphine plasma concentrations would be at or above the therapeutic threshold of 0.1 ng/mL and would not result in major injection site reactions.
Methods: Extended-release buprenorphine was administered once SC to 2 cohorts of adult female Yorkshire swine at low (0.2 mg/kg) and high doses (0.4 mg/kg). Blood was collected from an indwelling jugular catheter prior to and after XRB administration for 13 total time points. Buprenorphine plasma concentrations were analyzed by HPLC-MS, and pharmacokinetics were performed using a noncompartmental analysis.
Results: Extended-release buprenorphine was present in plasma at the therapeutic concentration of 0.1 ng/mL or above beginning at 8 hours and maintaining throughout 96 hours for all animals in both cohorts. Average plasma buprenorphine levels for both cohorts reached therapeutic concentrations starting at 1.5 hours and were maintained above therapeutic concentrations throughout 96 hours. The low-dose cohort's (n = 3) average half-life was 212.6 ± 107.1 hours, and the high-dose cohort's (n = 2) was 63.8 and 48.9 hours, respectively. The histology of SC sites revealed mild injection site reactions characterized by granulomatous inflammation with intralesional cholesterol cleft formation.
Conclusions: All animals reached and maintained therapeutic buprenorphine plasma concentrations of 0.1 ng/mL by 8 hours and maintained it to the end of the study at 96 hours.
Clinical relevance: Extended-release buprenorphine at either dose provides therapeutic levels of plasma buprenorphine, and therefore its use should be further investigated in swine.
期刊介绍：
The American Journal of Veterinary Research supports the collaborative exchange of information between researchers and clinicians by publishing novel research findings that bridge the gulf between basic research and clinical practice or that help to translate laboratory research and preclinical studies to the development of clinical trials and clinical practice. The journal welcomes submission of high-quality original studies and review articles in a wide range of scientific fields, including anatomy, anesthesiology, animal welfare, behavior, epidemiology, genetics, heredity, infectious disease, molecular biology, oncology, pharmacology, pathogenic mechanisms, physiology, surgery, theriogenology, toxicology, and vaccinology. Species of interest include production animals, companion animals, equids, exotic animals, birds, reptiles, and wild and marine animals. Reports of laboratory animal studies and studies involving the use of animals as experimental models of human diseases are considered only when the study results are of demonstrable benefit to the species used in the research or to another species of veterinary interest. Other fields of interest or animals species are not necessarily excluded from consideration, but such reports must focus on novel research findings. Submitted papers must make an original and substantial contribution to the veterinary medicine knowledge base; preliminary studies are not appropriate.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
